Seeking Alpha

Longboard Pharma's Lucrative Exit To Lundbeck Another Coup For Management

Longboard Pharmaceuticals is being acquired by Lundbeck for $60 per share, valuing the deal at $2.6 billion, driven by the potential of bexicaserin. Bexicaserin shows promising seizure reduction data, ...
Business Wire

Longboard Pharmaceuticals to Present at Three Upcoming Investor Conferences in November

LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological ...
Business Wire

Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15

PACIFIC Study Phase 1b/2a clinical data to be featured in a podium presentation at an Emerging Science Session at the AAN Annual Meeting Data will be featured in an encore presentation at the ...
Seeking Alpha

Longboard Pharmaceuticals: After Stellar Gains, A Period Of Relative Calm Seems Likely

Longboard Pharmaceuticals has seen a significant increase in its stock price following positive data from its Phase 1b/2a study of bexicaserin, a treatment for developmental and epileptic ...
Nasdaq

Longboard Pharmaceuticals Announces Positive Interim Analysis Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in ...

LA JOLLA, Calif.--(BUSINESS WIRE)-- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological ...